Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients

뉴스 본문을 불러오고 있어요.

Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients | 웨이프 WAPE

Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients

기사 요약

관련 종목

웨이프 AI가 분석했어요.

Coherus의 Tagmokitug 병용 요법이 초기 임상에서 75%의 반응률을 기록함.

댓글 —